SMITH & NEPHEW PLC Smith & Nephew plc Share Price Nyse
Equities
SNN
US83175M2052
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.85 USD | +0.54% |
|
+3.15% | -5.24% |
| Sales 2024 * | 5.82B 459B | Sales 2025 * | 6.12B 483B | Capitalization | 11.32B 894B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M 42.71B | Net income 2025 * | 694M 54.78B | EV / Sales 2024 * | 2.39 x |
| Net Debt 2024 * | 2.56B 202B | Net Debt 2025 * | 2.23B 176B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
16.9
x | Employees | 18,452 |
| Yield 2024 * |
2.94% | Yield 2025 * |
3.3% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew plc
More recommendations
More press releases
More news
| 1 day | +0.54% | ||
| 1 week | +3.15% | ||
| Current month | +7.13% | ||
| 1 month | +8.61% | ||
| 3 months | -7.88% | ||
| 6 months | +1.17% | ||
| Current year | -5.24% |
1 week
25.07
25.95
1 month
23.8025.95
Current year
23.6528.93
1 year
21.5332.71
3 years
21.5344.47
5 years
21.5352.26
10 years
21.5352.26
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 31/03/22 |
John Rogers
DFI | Director of Finance/CFO | 56 | 11-30 |
Alison Parkes
CMP | Compliance Officer | - | 31/03/99 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 30/09/17 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 13/09/23 |
Rupert Soames
CHM | Chairman | 63 | 25/04/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/05/24 | 25.85 | +0.54% | 906 351 |
| 15/05/24 | 25.71 | -0.23% | 874,140 |
| 14/05/24 | 25.77 | +2.63% | 991,825 |
| 13/05/24 | 25.11 | -0.44% | 735,221 |
| 10/05/24 | 25.22 | +0.64% | 603,138 |
Delayed Quote Nyse, May 16, 2024 at 09:00 pm
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92
USD
Average target price
16.35
USD
Spread / Average Target
+26.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.57% | 126B | |
| +3.22% | 9.12B | |
| +38.90% | 5.61B | |
| -21.83% | 4.75B | |
| +8.74% | 3.45B | |
| -6.82% | 2.89B | |
| -13.32% | 2.07B | |
| -6.99% | 2.05B | |
| -23.90% | 1.8B |
- Stock Market
- Equities
- SN. Stock
- SNN Stock
